The short version
What teams need to understand
- Pharmacovigilance vendors must be selected through a structured and documented evaluation process.
- Selection criteria must include capability, compliance, experience, systems, and regulatory alignment.
- Vendor selection must be supported by due diligence and risk assessment outputs.
- Final approval must be formally documented and authorised by PV, QA, and QPPV or delegated roles.
- Vendor selection decisions must be justified and traceable to evaluation criteria.
- Inspection-ready evidence must demonstrate that vendor selection is controlled, risk-based, and approved before engagement.
Regulatory expectation
What regulators expect
Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.
- Vendor selection must be based on defined and documented criteria.
- Selection decisions must be supported by due diligence and risk assessment.
- Vendor capability and compliance must be verified before approval.
- Approval must be formally authorised by appropriate roles.
- Vendor selection must be justified and traceable.
Why it matters
What this means in practice
Inspectors assess whether pharmacovigilance vendors are selected and approved through a structured, risk-based process. They typically review selection criteria, evaluation outputs, approval decisions, and evidence that the chosen vendor was justified and formally authorised before engagement.
Questions this page answers
Inspection evidence
Evidence teams should be able to show
Vendor Selection Criteria
- Defined criteria for evaluating vendor capability
- Assessment of PV process experience and expertise
- Evaluation of regulatory compliance and inspection history
- Assessment of IT systems, validation, and data security
- Geographic and regulatory coverage requirements
Vendor Shortlisting and Evaluation Records
- List of potential vendors considered
- Comparison of vendor capabilities and services
- Evaluation notes and scoring against criteria
- Justification for selecting preferred vendor
Due Diligence and Risk Assessment Outputs
- Completed vendor questionnaires
- Risk classification and rationale
- Audit outcomes or audit decision records
- Identification of strengths, weaknesses, and gaps
Vendor Approval Documentation
- Formal approval record for selected vendor
- QA and PV review of selection decision
- QPPV or delegated sign-off
- Documented justification for approval
Vendor Onboarding and Readiness Evidence
- Initial onboarding meeting records
- System access setup and validation checks
- Confirmation of process alignment with SOPs
- Defined communication and escalation pathways
Regulatory Basis (Primary Sources)
- GVP Module I - MAH responsibility for selection and oversight of third parties
- GVP Module VI - requirement for compliant handling of safety data through capable systems
- ICH E2D - need for reliable processes supporting safety data management
- MHRA GPvP guidance - expectations for vendor selection and qualification
- FDA pharmacovigilance guidance - responsibility for vendor selection and compliance remains with the MAH
Typical Inspection Questions (What Inspectors Ask)
- How did you select this vendor?
- What criteria were used to evaluate vendors?
- Why was this vendor chosen over others?
- Who approved the vendor and on what basis?
- Show me the documentation supporting this decision.
Common failure patterns
What good looks like
- A structured and documented vendor selection process.
- Clear evaluation criteria applied consistently across candidates.
- Evidence-based comparison and justification of vendor choice.
- Formal approval process involving PV, QA, and QPPV roles.
- Alignment between selected vendor capability and service requirements.
How teams operationalise it
- Define vendor selection criteria aligned with PV requirements.
- Create a shortlist of potential vendors based on service needs.
- Evaluate vendors using questionnaires, documentation review, and risk assessment.
- Document comparison and selection rationale.
- Obtain formal approval from PV, QA, and QPPV or delegated authority.
- Complete onboarding and confirm vendor readiness before starting activities.
From expectation to working control
Find the documentation that supports this work
Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.
Frequently asked questions
How do you choose a pharmacovigilance vendor?
A pharmacovigilance vendor is chosen through a structured process that includes defining selection criteria, shortlisting candidates, performing due diligence and risk assessment, comparing vendor capabilities, and obtaining formal approval based on documented evaluation.
How are pharmacovigilance vendors selected?
Vendors are selected through a structured evaluation process that assesses capability, compliance, experience, systems, and regulatory alignment against defined criteria.
Who approves a pharmacovigilance vendor?
Vendor approval is typically performed by PV Operations, Quality Assurance, and the QPPV or delegated authority based on documented evaluation and risk assessment.
What criteria are used to select a PV vendor?
Criteria typically include PV expertise, regulatory compliance history, system validation, data security, geographic coverage, and operational capability.
Do inspectors review vendor selection decisions?
Yes. Inspectors review how vendors were selected, what criteria were applied, and whether the decision was justified and formally approved.
What happens if vendor selection is not properly documented?
Lack of documentation can result in inspection findings, as regulators expect clear justification for vendor selection decisions.
What is the vendor onboarding process in pharmacovigilance?
Onboarding includes contract execution, SDEA setup, system access configuration, process alignment, and confirmation that the vendor is ready to perform PV activities.
Source boundary
Regulatory sources
These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.
European Medicines Agency (EMA)
Guideline on good pharmacovigilance practices (GVP) - Module I
View sourceGuideline on good pharmacovigilance practices (GVP) - Module VI
View source
FDA
Postmarketing Safety Reporting
View source
ICH
Post-Approval Safety Data Management (E2D)
View source
MHRA
Good Pharmacovigilance Practice (GPvP)
View source